1. Home
  2. BAX vs VTRS Comparison

BAX vs VTRS Comparison

Compare BAX & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BAX
  • VTRS
  • Stock Information
  • Founded
  • BAX 1931
  • VTRS 1961
  • Country
  • BAX United States
  • VTRS United States
  • Employees
  • BAX N/A
  • VTRS N/A
  • Industry
  • BAX Medical/Dental Instruments
  • VTRS Medicinal Chemicals and Botanical Products
  • Sector
  • BAX Health Care
  • VTRS Health Care
  • Exchange
  • BAX Nasdaq
  • VTRS Nasdaq
  • Market Cap
  • BAX 15.1B
  • VTRS 15.6B
  • IPO Year
  • BAX N/A
  • VTRS N/A
  • Fundamental
  • Price
  • BAX $28.91
  • VTRS $12.26
  • Analyst Decision
  • BAX Hold
  • VTRS Hold
  • Analyst Count
  • BAX 10
  • VTRS 3
  • Target Price
  • BAX $40.90
  • VTRS $13.67
  • AVG Volume (30 Days)
  • BAX 4.4M
  • VTRS 7.1M
  • Earning Date
  • BAX 02-06-2025
  • VTRS 11-07-2024
  • Dividend Yield
  • BAX 3.60%
  • VTRS 3.92%
  • EPS Growth
  • BAX N/A
  • VTRS N/A
  • EPS
  • BAX 0.21
  • VTRS N/A
  • Revenue
  • BAX $15,062,000,000.00
  • VTRS $15,048,500,000.00
  • Revenue This Year
  • BAX N/A
  • VTRS N/A
  • Revenue Next Year
  • BAX $6.71
  • VTRS N/A
  • P/E Ratio
  • BAX $136.05
  • VTRS N/A
  • Revenue Growth
  • BAX 32.37
  • VTRS N/A
  • 52 Week Low
  • BAX $28.90
  • VTRS $9.93
  • 52 Week High
  • BAX $44.01
  • VTRS $13.62
  • Technical
  • Relative Strength Index (RSI)
  • BAX 21.08
  • VTRS 40.42
  • Support Level
  • BAX $30.77
  • VTRS $12.37
  • Resistance Level
  • BAX $30.29
  • VTRS $13.13
  • Average True Range (ATR)
  • BAX 0.73
  • VTRS 0.30
  • MACD
  • BAX -0.24
  • VTRS -0.11
  • Stochastic Oscillator
  • BAX 0.20
  • VTRS 1.00

About BAX Baxter International Inc.

Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter has signed an agreement to sell its kidney care tools by early 2025.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: